id.DRIVE RSV Vaccine Effectiveness Study

• Research type

  Research Study

• Full title

  Brand-specific respiratory syncytial virus vaccine effectiveness in Europe A contribution of id.DRIVE, a public-private partnership to facilitate the conduct of observational studies on infectious diseases, vaccines, related preventive measures and therapeutics for infectious diseases in Europe

• IRAS ID

  343291

• Contact name

  Thomas Verstraeten

• Contact email

  thomas.verstraeten@P-95.com

• Sponsor organisation

  P95

• Clinicaltrials.gov Identifier

  1000000035, EUPAS

• Duration of Study in the UK

  1 years, 0 months, 1 days

• Research summary

  This protocol describes a European, non-interventional study to estimate the effectiveness of vaccines) against respiratory syncytial virus (RSV). Of interest is the effectiveness against hospitalisation due to severe acute respiratory infection (SARI) caused by RSV. The study is a multi-country, hospital-based study with test-negative case-control (TNCC) design.

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  24/PR/1101

• Date of REC Opinion

  7 Mar 2025

• REC opinion

  Further Information Favourable Opinion